Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The effects of supraphysiological recombinant human GH (rhGH) on GH resistance in AN are not currently known.

Who Took Part

According to the abstract, 21 women were involved.

The age groups tagged for this paper are adults, women only.

How the Study Was Run

The design is described as randomized and placebo-controlled.

The women were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

The researchers conducted a randomized, placebo-controlled study in a Clinical Research Center.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Analysis of Variance, Anorexia Nervosa, Blood Glucose, Body Composition, Collagen Type I and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 21 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.